Sorafenib in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (SCLC): A Southwest Oncology Group (SWOG 0435) Phase II Trial

INTRODUCTION: Sorafenib is a multi-kinase inhibitor affecting pathways involved in tumor progression and angiogenesis. We conducted a phase II trial of Sorafenib in platinum-treated extensive stage small cell lung cancer (SCLC) patients to determine the tumor response rate, toxicity and overall surv...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Gitlitz, Barbara J., Moon, James, Glisson, Bonnie S., Reimers, H. Joachim, Bury, Martin J., Floyd, Justin D., Schulz, Thomas K., Sundaram, P. Kothai, Ho, Christopher, Gandara, David R.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3676180/
https://ncbi.nlm.nih.gov/pubmed/20881645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181f0bd78
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires